EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Interim analysis of the long‐term efficacy and safety of azetukalner in an ongoing open‐label extension study following a phase 2b clinical trial (X‐ TOLE ) in adults with focal epilepsy

Jacqueline A French iD, Roger J Porter, Emilio Perucca, Martin J Brodie iD, Michael A Rogawski iD, Cynthia Harden, Jenny Qian, Constanza Luzon Rosenblut, Christopher Kenney, Gregory N Beatch, X‐TOLE Study Group

Epilepsia Open · 2025-04 · 10 (2) · 539-548

DOI: 10.1002/epi4.70015 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Epilepsia Open, online erschienen am 07.03.2025. Verfasst von Jacqueline A French und 10 weiteren Autor:innen. Beteiligte Einrichtung: New York University Comprehensive Epilepsy Center, New York, New York, USA. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsies, Partial. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Xenon Pharmaceuticals Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To report interim data from an ongoing, open‐label extension (OLE) of a Phase 2b study (X‐TOLE) of azetukalner in adults with focal onset seizures (FOS) receiving 1–3 antiseizure medications.

Methods

Eligible participants enrolled in the 7‐year OLE at 20 mg azetukalner once daily with food. Long‐term seizure outcomes included median percentage change (MPC) in monthly (28 days) FOS frequency from the double‐blind phase (DBP) baseline and achievement of ≥50%, ≥75%, ≥90%, and 100% seizure reductions.

Results

285 participants completed the DBP, and 275 (96.5%) enrolled in the OLE. At the 24‐month interim analysis (September 5, 2023), 182 participants had been treated for ≥12 months and 165 for ≥24 months; 152 (55.3%) continued in the study. The median (range) treatment duration in the OLE was 26.3 (0.1–46.6) months. MPC reduction was 83.2% at 24 months in the OLE vs. DBP baseline. For all participants who entered the OLE, 56.4% (155/275) and 44.4% (122/275) achieved a ≥50% seizure reduction, 28.4% (78/275) and 19.6% (54/275) achieved a ≥90% seizure reduction, and 22.2% (61/275) and 14.9% (41/275) achieved seizure freedom (100% seizure reduction) for any consecutive ≥6‐ and ≥12‐month period, respectively. For those who reached ≥24 months in the OLE, seizure freedom was achieved by 34.5% (57/165) and 23.6% (39/165) for any consecutive ≥6‐ and ≥12‐month period, respectively. The majority of treatment‐emergent adverse events (TEAEs) were mild or moderate. The most common TEAEs were dizziness (21.8%), headache (15.3%), coronavirus infection (15.3%), somnolence (12.7%), fall (12.7%), and memory impairment (10.9%). Serious AEs were reported in 35 (12.7%) participants. Significance The efficacy demonstrated by azetukalner in reducing FOS seizure frequency in the DBP was sustained in this interim analysis. Azetukalner was generally well tolerated, with no new safety signals compared to the DBP. These data suggest sustained long‐term efficacy and safety of azetukalner in a difficult‐to‐treat population. Plain Language Summary This long‐term study assessed the safety and efficacy of azetukalner to treat focal seizures. Patients taking azetukalner daily with food for about 2 years had far fewer focal seizures with azetukalner than before taking the medication. For those who had been treated for 24 months, about a third were seizure‐free for a consecutive 6‐month period, and about a quarter were seizure‐free for a consecutive 12‐month period. Most side effects were mild or moderate, and these included dizziness, headache, and somnolence (sleepiness).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEpilepsies, PartialAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultDouble-Blind MethodSeizuresTreatment Outcome

Stichwörter der Autor:innen

antiseizure medicationazetukalnerepilepsyfocal seizureopen‐label trialpotassium channel opener

Substanzen

Anticonvulsants

Autor:innen und Institutionen

  • New York University Comprehensive Epilepsy Center, New York, New York, USA.
  • University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Medicine (Austin Health), The University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Neuroscience, Monash University, Melbourne, Victoria, Australia.
  • University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, UK.
  • School of Medicine, University of California, Davis, Sacramento, California, USA.

ORCID-Profile: Jacqueline A French, Martin J Brodie, Michael A Rogawski

Förderung

  • Xenon Pharmaceuticals Inc.

Zitieren

APA

French, J. A., Porter, R. J., Perucca, E., Brodie, M. J., Rogawski, M. A., Harden, C., Qian, J., Rosenblut, C. L., Kenney, C., Beatch, G. N., & X‐TOLE Study Group (2025). Interim analysis of the long‐term efficacy and safety of azetukalner in an ongoing open‐label extension study following a phase 2b clinical trial (X‐ TOLE ) in adults with focal epilepsy. Epilepsia Open, 10(2), 539-548. https://doi.org/10.1002/epi4.70015

Vancouver

French JA, Porter RJ, Perucca E, Brodie MJ, Rogawski MA, Harden C, et al. Interim analysis of the long‐term efficacy and safety of azetukalner in an ongoing open‐label extension study following a phase 2b clinical trial (X‐ TOLE ) in adults with focal epilepsy. Epilepsia Open. 2025;10(2):539-548. doi:10.1002/epi4.70015

BibTeX
@article{French2025,
  author = {French, Jacqueline A and Porter, Roger J and Perucca, Emilio and Brodie, Martin J and Rogawski, Michael A and Harden, Cynthia and Qian, Jenny and Rosenblut, Constanza Luzon and Kenney, Christopher and Beatch, Gregory N and X‐TOLE Study Group, X‐TOLE Study Group},
  title = {Interim analysis of the long‐term efficacy and safety of azetukalner in an ongoing open‐label extension study following a phase 2b clinical trial (X‐ TOLE ) in adults with focal epilepsy},
  journal = {Epilepsia Open},
  year = {2025},
  volume = {10},
  number = {2},
  pages = {539--548},
  doi = {10.1002/epi4.70015}
}
Kostenlos starten →